Sanofi Pasteur Set To Ship Japan’s First Foreign Hib Vaccine
This article was originally published in PharmAsia News
Executive Summary
The head of France-based Sanofi Pasteur said Japan's first foreign-made vaccine for hemophilus influenza type B is expected to be on the market by December. The drug is notable for being the first vaccine licensed by a multinational drug maker to be sold in Japan. Sanofi President Wayne Pisano said strict Japanese approval requirements had delayed the vaccine being allowed there even as it was available in other countries. The infectious disease affects children under 5 with meningitis and pneumonia. Japan expects to receive about 500,000 doses of the vaccine each year. The company make